Director/PDMR Shareholding

RNS Number : 3462T

Hutchison China Meditech Limited

29 March 2016

 

Director's Shareholding

London: Tuesday, March 29, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on March 25, 2016 that Mr Christian Hogg, Executive Director and Chief Executive Officer, has purchased 36,600 American Depositary Shares ("ADSs", each representing one-half of one ordinary share) of the Company at a price of US$13.5 per ADS on March 25, 2016. 

Following this purchase, Mr Hogg is beneficially interested in 36,600 ADSs and 1,088,182 ordinary shares, representing approximately 1.84% of the current issued share capital of Chi-Med.

Ends

Contact

Investor Enquiries
Christian Hogg, CEO	[phone]
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson	[phone] (Mobile)
US-Based Media Enquiries
Brad Miles, BMC Communications	[phone]
Susan Duffy, BMC Communications	[phone]
Investor Relations
Jillian Connell, The Trout Group	[phone]
David Dible, Citigate Dewe Rogerson	[phone] [phone] (Mobile)
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts	[phone]

 

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

END

 

 

RDSGLGDXCUDBGLC